Introduction：Basic information about CAS 220997-97-7|Diflomotecan, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Diflomotecan |
|---|
| CAS Number | 220997-97-7 | Molecular Weight | 398.359 |
|---|
| Density | 1.6±0.1 g/cm3 | Boiling Point | 784.2±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C21H16F2N2O4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 428.1±32.9 °C |
|---|
Names
| Name | diflomotecan |
|---|
| Synonym | More Synonyms |
|---|
Diflomotecan BiologicalActivity
| Description | Diflomotecan (BN 80915) is a potent inhibitor of topoisomerase I. Diflomotecan causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds[1]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Cell Cycle/DNA Damage >>Topoisomerase |
|---|
| Target | topoisomerase I[1] |
|---|
| References | [1]. Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18(1):69-75. |
|---|
Chemical & Physical Properties
| Density | 1.6±0.1 g/cm3 |
|---|
| Boiling Point | 784.2±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C21H16F2N2O4 |
|---|
| Molecular Weight | 398.359 |
|---|
| Flash Point | 428.1±32.9 °C |
|---|
| Exact Mass | 398.107819 |
|---|
| LogP | 1.73 |
|---|
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.696 |
|---|
| InChIKey | LFQCJSBXBZRMTN-OAQYLSRUSA-N |
|---|
| SMILES | CCC1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(F)c(F)cc3nc2-1 |
|---|
Synonyms
| diflomotecan |
| QKT1LC4J1P |
| 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5R)- |
| 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5R)- |
| (5R)-5-Ethyl-9,10-difluoro-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione |
